Description
Avamis (Fluticasone Furoate) Nasal Spray 27.5 mcg/dose 120 doses №1
Ingredients
Active ingredient: Fluticasone furoate. Other ingredients include microcrystalline cellulose, carboxymethylcellulose sodium, dextrose, polysorbate 80, purified water, and benzalkonium chloride.
Mechanism of Action
Fluticasone furoate, a synthetic corticosteroid, exerts its anti-inflammatory effects by binding to glucocorticoid receptors. This action leads to the inhibition of inflammatory mediators, thereby reducing the symptoms of allergic rhinitis.
Pharmacological Properties
The pharmacological properties of Avamis nasal spray are attributed to the potent anti-inflammatory activity of fluticasone furoate. This corticosteroid acts locally in the nasal mucosa to suppress inflammation and allergic responses, providing relief from nasal congestion, itching, and sneezing.
Indications for Use
Avamis nasal spray is indicated for the treatment of symptoms of allergic rhinitis in adults and pediatric patients aged 2 years and above. It is effective in alleviating nasal congestion, rhinorrhea, sneezing, and nasal itching associated with allergic rhinitis.
Contraindications
Avamis nasal spray should not be used in individuals with a known hypersensitivity to fluticasone furoate or any of the other components present in the formulation. Patients with untreated nasal infections should also avoid using this product.
Side Effects
Common side effects of Avamis nasal spray may include nasal irritation, epistaxis, headache, and unpleasant taste or smell. Rarely, systemic effects such as adrenal suppression or glaucoma may occur, especially with prolonged use at high doses.
Usage Instructions
Dosage: The recommended dose of Avamis nasal spray is 2 sprays in each nostril once daily. It is essential to follow the prescribed regimen and avoid exceeding the recommended dosage to minimize the risk of adverse effects.
Benefits Compared to Analogues
Avamis nasal spray offers a distinct advantage over other intranasal corticosteroids due to the unique formulation of fluticasone furoate, which provides superior efficacy in managing allergic rhinitis symptoms. Its once-daily dosing regimen enhances patient compliance and convenience.
Suitable Patient Groups
Avamis nasal spray is suitable for a wide range of patient populations, including children aged 2 years and older, adults, and the elderly. Its safety and efficacy profile make it a preferred choice for individuals requiring long-term management of allergic rhinitis.
Storage Conditions and Shelf Life
- Storage: Keep Avamis nasal spray at room temperature, protected from moisture and heat. Avoid freezing the product.
- Shelf Life: Check the expiration date on the packaging and do not use the product beyond the specified shelf life.
Packaging Description
Avamis nasal spray is available in a convenient packaging containing 120 doses per unit. The spray pump is designed for easy administration, ensuring accurate dosing with each use.
Clinical Evidence and Proven Effectiveness
Avamis (fluticasone furoate) nasal spray has undergone rigorous clinical trials to assess its efficacy and safety in the management of allergic rhinitis. Studies have consistently demonstrated the superior effectiveness of fluticasone furoate in reducing nasal symptoms compared to placebo.
The safety profile of Avamis nasal spray has been well-established through various clinical trials, highlighting its favorable risk-benefit ratio in the treatment of allergic rhinitis. Patients can rely on the proven effectiveness of fluticasone furoate for symptom relief and improved quality of life.
